GSK (GSK) Stock: Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 14, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: None
Big funds13F, quarter ended Jun 30, 2026: 4 added, 0 cut
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about GSK filings

Are insiders buying or selling GSK plc (GSK) stock?

Neither. GSK plc (GSK) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded GSK recently?

None. No member of Congress disclosed a GSK trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this GSK smart-money data?

This summary uses filings available on Nov 14, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

Filings could not be loaded.

26 funds hold a position.

Questions about GSK filings

Are insiders buying or selling GSK plc (GSK) stock?

Neither. GSK plc (GSK) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded GSK recently?

None. No member of Congress disclosed a GSK trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this GSK smart-money data?

Funds

What funds are doing

4 moves · 6 mo

Buys/Adds$297.5M

Buys/Adds (3)

P7
Point72
Steven Cohen · Q2 2026 13F
$139.1M
bought
Signals like this: n=3228, 54% finished lower at D15, median -0.8% vs SPY -0.4%
DS
D.E. Shaw
Q2 2026 13F
$53.4M
bought
QR
Qube Research
Q2 2026 13F
$26.3M
added
Signals like this: n=13773, 53% finished lower at D15, median -0.4% vs SPY -0.4%

1 more moves

Pro opens all of them for $16.50/month, paid yearly.

Unlock all 1 moves

Unlock everything for $29/month

Unlock for $29/month

Reported Oct 28, 2026

Earnings came in 5.0% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Oct 28, 2026

Period ending

Sep 30, 2026

Earnings per share

$1.47+5.00% beat

$1.40 expected

Revenue

GBP 8.89B

Yahoo Finance

Revenue: Yahoo Finance

Next report

What the street expects next

Estimates as of Nov 10, 2026

EPS expected

$0.74

$0.73 to $0.75

Revenue expected

$8.87B

7 analysts

Last 30 days

0up1down

Analysts cutting estimates

Estimate drift

0.06

Change in 30 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Oct 28, 2026	$1.47est. $1.40	+5.00%beat	GBP 8.89BYahoo Finance	+4.0%from GBP 8.55B
Jun 30, 2026Reported Jul 28, 2026	$1.36est. $1.27	+7.09%beat	GBP 8.41BAlpha Vantage	No year-ago quarter
Mar 31, 2026Reported Apr 29, 2026	$1.26est. $1.16	+8.62%beat	GBP 7.63BAlpha Vantage	+1.5%from GBP 7.52B
Dec 31, 2025Reported Feb 4, 2026	$0.70est. $0.62	+12.90%beat	$8.62BAlpha Vantage	No year-ago quarter
Sep 30, 2025Reported Oct 29, 2025	$1.46est. $1.26	+15.87%beat	GBP 8.55BAlpha Vantage	+6.7%from GBP 8.01B
Jun 30, 2025Reported Jul 30, 2025	$1.24est. $1.11	+11.71%beat	$7.99BAlpha Vantage	No year-ago quarter
Mar 31, 2025Reported Apr 30, 2025	$1.20est. $1.04	+15.38%beat	GBP 7.52BAlpha Vantage	+2.1%from GBP 7.36B
Dec 31, 2024Reported Feb 5, 2025	$0.58est. $0.49	+18.37%beat	GBP 8.12BAlpha Vantage	+0.8%from GBP 8.05B

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $50.19
High: $50.64
Low: $49.79
Prev close: $51.23
52-wk high: $59.58
52-wk low: $44.24
Mkt cap: $101.43B
P/E: 17.6x
ROE: +28.3%
Fwd P/E: 10.1x
Beta: 0.28
Div yield: 3.59%
P/S: 3.0x
P/B: 4.1x
Profit margin: +13.0%
Op margin: +30.5%

Jun 2025 to Dec 2025

What it sold, what it cost, what was left.

RevenueProfit

Jun 2025Dec 2025

Income statement, 2 periods, all values in US dollars
USD	Jun 2025	Dec 2025
What came in
RevenueTotal revenue	$7.99B	$8.62B
Cost of what it soldCost of revenue	$2.17B	$2.66B
Gross profit	$5.82B	$5.96B
What it spent
Research and development	$2.02B	$2.35B
Sales and adminSelling, general and administrative	$2.14B	$2.64B
Other operating costsOperating costs not itemised in the filing's summary	-$366.0M	-$534.0M
Total operating expenses	$3.80B	$4.46B
What was left
Operating profitOperating income	$2.02B	$1.51B
Interest on debtInterest expense	$184.0M	$174.0M
Profit before tax	$1.89B	$950.0M
TaxIncome tax expense	$241.0M	$223.0M
Net profitNet income	$1.44B	$636.0M
EBITDAEarnings before interest, tax, depreciation, amortisation	$3.23B	$1.91B

Technicals

Price structure

This stock is trending upward.

Trend

Constructive

75 / 100

RSI 14

47balanced

20D volatility

32%annualized

52-week range

$50.61

$44.24$59.58

20D support

$47.35recent floor

20D resistance

$51.89recent ceiling

Returns

5D -1.1%20D +5.7%60D -1.1%

Price vs moving averages

SMA20 +1.0%SMA50 +2.7%SMA200 -2.4%

Volume pace

0.84xvs prior 20D

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Sep 30, 2026Oct 28, 2026

$1.47est. $1.40

+5.00%

GBP 8.89BYahoo Finance

+4.0%from GBP 8.55B

Jun 30, 2026Jul 28, 2026

$1.36est. $1.27

+7.09%

GBP 8.41BAlpha Vantage

No year-ago quarter

Mar 31, 2026Apr 29, 2026

$1.26est. $1.16

+8.62%

GBP 7.63BAlpha Vantage

+1.5%from GBP 7.52B

Dec 31, 2025Feb 4, 2026

$0.70est. $0.62

+12.90%

$8.62BAlpha Vantage

No year-ago quarter

Sep 30, 2025Oct 29, 2025

$1.46est. $1.26

+15.87%

GBP 8.55BAlpha Vantage

+6.7%from GBP 8.01B

Jun 30, 2025Jul 30, 2025

$1.24est. $1.11

+11.71%

$7.99BAlpha Vantage

No year-ago quarter

Mar 31, 2025Apr 30, 2025

$1.20est. $1.04

+15.38%

GBP 7.52BAlpha Vantage

+2.1%from GBP 7.36B

Dec 31, 2024Feb 5, 2025

$0.58est. $0.49

+18.37%

GBP 8.12BAlpha Vantage

+0.8%from GBP 8.05B

Income statement, 2 periods, all values in US dollars
USD	Jun 2025	Dec 2025
What came in
RevenueTotal revenue	$7.99B	$8.62B
Cost of what it soldCost of revenue	$2.17B	$2.66B
Gross profit	$5.82B	$5.96B
What it spent
Research and development	$2.02B	$2.35B
Sales and adminSelling, general and administrative	$2.14B	$2.64B
Other operating costsOperating costs not itemised in the filing's summary	-$366.0M	-$534.0M
Total operating expenses	$3.80B	$4.46B
What was left
Operating profitOperating income	$2.02B	$1.51B
Interest on debtInterest expense	$184.0M	$174.0M
Profit before tax	$1.89B	$950.0M
TaxIncome tax expense	$241.0M	$223.0M
Net profitNet income	$1.44B	$636.0M
EBITDAEarnings before interest, tax, depreciation, amortisation	$3.23B	$1.91B

USD

Jun 2025

Dec 2025

What came in

RevenueTotal revenue

$7.99B

$8.62B

Cost of what it soldCost of revenue

$2.17B

$2.66B

Gross profit

$5.82B

$5.96B

What it spent

Research and development

$2.02B

$2.35B

Sales and adminSelling, general and administrative

$2.14B

$2.64B

Other operating costsOperating costs not itemised in the filing's summary

-$366.0M

-$534.0M

Total operating expenses

$3.80B

$4.46B

What was left

Operating profitOperating income

$2.02B

$1.51B

Interest on debtInterest expense

$184.0M

$174.0M

Profit before tax

$1.89B

$950.0M

TaxIncome tax expense

$241.0M

$223.0M

Net profitNet income

$1.44B

$636.0M

EBITDAEarnings before interest, tax, depreciation, amortisation

$3.23B

$1.91B

GSK plc

Smart money at a glance

What do analysts expect?

Questions about GSK filings

Questions about GSK filings

What funds are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 5.0% above what analysts expected.

What the street expects next

Previous reports

What it sold, what it cost, what was left.

Price structure

Ask it in Claude or ChatGPT.

GSK plc

Smart money at a glance

What do analysts expect?

Questions about GSK filings

Questions about GSK filings

What funds are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 5.0% above what analysts expected.

What the street expects next

Previous reports

What it sold, what it cost, what was left.

Price structure

Ask it in Claude or ChatGPT.

GSK plc

Overview

Questions about GSK filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

GSK plc

Overview

Questions about GSK filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.